{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:59:29Z","timestamp":1780822769976,"version":"3.54.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PTJ-156256"],"award-info":[{"award-number":["PTJ-156256"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["WI2 179934"],"award-info":[{"award-number":["WI2 179934"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Social Science & Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.socscimed.2025.118687","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:02:47Z","timestamp":1760731367000},"page":"118687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Public sector innovation and the constraints of \u2018platform thinking\u2019: An account of Johnson & Johnson's adenoviral vector vaccines"],"prefix":"10.1016","volume":"387","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-5267","authenticated-orcid":false,"given":"Karim","family":"Sariahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-8122","authenticated-orcid":false,"given":"Janice E.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5319-6199","authenticated-orcid":false,"given":"Matthew","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Morten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib1","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.socscimed.2025.118687_bib2","author":"Baker"},{"issue":"49","key":"10.1016\/j.socscimed.2025.118687_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"Chadox1 interacts with car and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0048-7333(03)00108-2","article-title":"Networks of inventors and the role of academia: an exploration of Italian patent data","volume":"33","author":"Balconi","year":"2004","journal-title":"Res. Pol."},{"issue":"12","key":"10.1016\/j.socscimed.2025.118687_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003940","article-title":"Technology transfer, intellectual property, and the fight for the soul of WHO","volume":"4","author":"Barber","year":"2024","journal-title":"PLOS Global Public Health"},{"issue":"10","key":"10.1016\/j.socscimed.2025.118687_bib6","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol. (Baltimore, Md.: 1950"},{"issue":"2","key":"10.1016\/j.socscimed.2025.118687_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/hum.2005.16.149","article-title":"Adenovirus vector-based vaccines for human immunodeficiency virus type 1","volume":"16","author":"Barouch","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.socscimed.2025.118687_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1","volume":"5","author":"Barouch","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"10","key":"10.1016\/j.socscimed.2025.118687_bib9","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.socscimed.2025.118687_bib11","author":"Bayer"},{"issue":"2","key":"10.1016\/j.socscimed.2025.118687_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.36646\/mjlr.56.2.inequitable","article-title":"Inequitable by design: the patent culture, law, and politics behind COVID-19 vaccine global access","volume":"56","author":"Benavides","year":"2023","journal-title":"Univers. Michigan J. Law Reform"},{"issue":"2","key":"10.1016\/j.socscimed.2025.118687_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/twec.13183","article-title":"How COVID-19 vaccine supply chains emerged in the midst of a pandemic","volume":"45","author":"Bown","year":"2022","journal-title":"World Econ."},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0162243916661633","article-title":"Rethinking value in the bio-economy: finance, assetization, and the management of value","volume":"42","author":"Birch","year":"2016","journal-title":"Sci. Technol. Hum. Val."},{"key":"10.1016\/j.socscimed.2025.118687_bib16","series-title":"Immunization and States: the Politics of Making Vaccines","year":"2022"},{"key":"10.1016\/j.socscimed.2025.118687_bib17","author":"Brown"},{"issue":"2","key":"10.1016\/j.socscimed.2025.118687_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJMms2308188","article-title":"The financialization of health in the United States","volume":"390","author":"Bruch","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9653","key":"10.1016\/j.socscimed.2025.118687_bib19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.socscimed.2025.118687_bib20","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1007\/s00253-018-9091-5","article-title":"Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system","volume":"102","author":"Chen","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"4","key":"10.1016\/j.socscimed.2025.118687_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/03063127241303720","article-title":"A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies","volume":"55","author":"Chiapperino","year":"2025","journal-title":"Soc. Stud. Sci."},{"key":"10.1016\/j.socscimed.2025.118687_bib22","series-title":"Situational Analysis: Grounded Theory After the Interpretive Turn","author":"Clarke","year":"2018"},{"key":"10.1016\/j.socscimed.2025.118687_bib23","series-title":"Between Truth & Power: the Legal Construction of Information Capitalism","author":"Cohen","year":"2019"},{"key":"10.1016\/j.socscimed.2025.118687_bib24","article-title":"Gold standard or appalling? HHS's $500 million vaccine bet on inactivated viruses puzzles field","author":"Cohen","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.socscimed.2025.118687_bib25","series-title":"Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health, and Pharmaceuticals","article-title":"Brazil: patent barriers and access to medicines through the public health system","author":"Costa Chaves","year":"2021"},{"issue":"22","key":"10.1016\/j.socscimed.2025.118687_bib26","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent AD26 viral vectors: standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"Custers","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.socscimed.2025.118687_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10272-021-1009-2","article-title":"Policy lessons from medical responses to the COVID-19 crisis","volume":"56","author":"Dosi","year":"2021","journal-title":"Intereconomics"},{"key":"10.1016\/j.socscimed.2025.118687_bib29","series-title":"The Top 20 Pharma Companies by 2023 Revenue","author":"Dunleavy","year":"2024"},{"key":"10.1016\/j.socscimed.2025.118687_bib30","series-title":"U.S. to Pay $1 Billion for 100 Million Doses of Johnson & Johnson's COVID-19 Vaccine Candidate","author":"Erman","year":"2020"},{"issue":"6538","key":"10.1016\/j.socscimed.2025.118687_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.abi8397","article-title":"The story behind Covid-19 vaccines","volume":"372","author":"Fauci","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.socscimed.2025.118687_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and safety of an ad26.rsv.pref\u2013RSV PREF protein vaccine in older adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antib11010007","article-title":"Antibodies against platelet factor 4 and their associated pathologies: from hit\/hitt to spontaneous hit-like syndrome, to COVID-19, to Vitt\/TTS","volume":"11","author":"Favaloro","year":"2022","journal-title":"Antibodies"},{"issue":"6","key":"10.1016\/j.socscimed.2025.118687_bib36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1287\/orsc.1070.0289","article-title":"Small worlds and regional innovation","volume":"18","author":"Fleming","year":"2007","journal-title":"Organ. Sci."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1142\/S0219525907000921","article-title":"The evolution of inventor networks in the silicon valley and Boston regions","volume":"10","author":"Fleming","year":"2007","journal-title":"Adv. Complex Syst."},{"issue":"539","key":"10.1016\/j.socscimed.2025.118687_bib39","first-page":"543","article-title":"Patent disclosure","volume":"94","author":"Fromer","year":"2009","journal-title":"Univers. Iowa Law Rev."},{"issue":"46","key":"10.1016\/j.socscimed.2025.118687_bib40","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1016\/j.vaccine.2009.06.028","article-title":"Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity","volume":"27","author":"Gabitzsch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.socscimed.2025.118687_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.socscimed.2016.03.025","article-title":"The social management of biomedical novelty: facilitating translation in regenerative medicine","volume":"156","author":"Gardner","year":"2016","journal-title":"Soc. Sci. Med."},{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib42","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (AD26) and AD35 vaccine vectors bypass immunity to AD5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.socscimed.2025.118687_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthplace.2023.103051","article-title":"Global inequities in access to COVID-19 health products and technologies: a political economy analysis","volume":"83","author":"Gleeson","year":"2023","journal-title":"Health Place"},{"key":"10.1016\/j.socscimed.2025.118687_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.socscimed.2025.118687_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000990","article-title":"Prepared for the \u2018unexpected\u2019? Lessons from the 2014\u20132016 Ebola epidemic in West Africa on integrating emergent theory designs into outbreak response","volume":"3","author":"Graham","year":"2018","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.socscimed.2025.118687_bib48","series-title":"Science, Information, and Policy Interface for Effective Coastal and Ocean Management","first-page":"325","article-title":"Just evidence: opening health knowledge to a parliament of evidence","author":"Graham","year":"2016"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib49","first-page":"31","article-title":"Mild cognitive impairment: ethical considerations for nosological flexibility in human kinds","volume":"13","author":"Graham","year":"2006","journal-title":"Philos. Psychiatr. Psychol."},{"key":"10.1016\/j.socscimed.2025.118687_bib50","article-title":"Johnson & Johnson buys 18 pct stake in Crucell","author":"Gray-Block","year":"2009","journal-title":"Reuters"},{"key":"10.1016\/j.socscimed.2025.118687_bib51","article-title":"TAKE-A-LOOK-Crucell to be delisted after J&J buyout","author":"Gray-Block","year":"2011","journal-title":"Reuters"},{"key":"10.1016\/j.socscimed.2025.118687_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijid.2018.06.022","article-title":"Ebola vaccine development: systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination","volume":"74","author":"Gross","year":"2018","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib53","first-page":"28","article-title":"The future of pandemic vaccine access","volume":"55","author":"Halabi","year":"2022","journal-title":"N. Y. Univ. J. Int. Law Polit."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib54","doi-asserted-by":"crossref","DOI":"10.2307\/3313062","article-title":"The situation: an introduction to the situational character, critical realism, power economics, and deep capture","volume":"152","author":"Hanson","year":"2003","journal-title":"Univ. Penn. Law Rev."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00833-z","article-title":"Heterologous Cad3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1\/1B trials","volume":"9","author":"Happe","year":"2024","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.socscimed.2025.118687_bib56","series-title":"Cyborgs & Citadels: Anthropological Interventions in Emerging Sciences and Technologies","first-page":"209","article-title":"Mice into wormholes: a comment on the nature of no nature","author":"Haraway","year":"1997"},{"issue":"12","key":"10.1016\/j.socscimed.2025.118687_bib57","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ensemble2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003173","article-title":"\u2018Our project, your problem?\u2019 A case study of the WHO's mRNA technology transfer programme in South Africa","volume":"4","author":"Herder","year":"2024","journal-title":"PLOS Global Public Health"},{"issue":"4","key":"10.1016\/j.socscimed.2025.118687_bib59","first-page":"15","article-title":"University technology transfer has failed to improve access to global health products during the COVID-19 pandemic","volume":"17","author":"Herder","year":"2022","journal-title":"Healthc. Policy"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsz019","article-title":"From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine","volume":"7","author":"Herder","year":"2020","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.socscimed.2025.118687_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)60140-4","article-title":"Human adenovirus vectors for gene transfer into mammalian cells","author":"Hitt","year":"1997","journal-title":"Adv. Pharmacol."},{"issue":"8","key":"10.1016\/j.socscimed.2025.118687_bib62","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1128\/JVI.73.8.6930-6936.1999","article-title":"Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo","volume":"73","author":"Hofmann","year":"1999","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/rego.12360","article-title":"The ratio of vision to data: promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine","volume":"15","author":"Hogarth","year":"2021","journal-title":"Regulat. Govern."},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/omi.2010.0022","article-title":"Standardization and OMICS SCIENCE: technical and social dimensions are inseparable and demand symmetrical study","volume":"14","author":"Holmes","year":"2010","journal-title":"OMICS A J. Integr. Biol."},{"key":"10.1016\/j.socscimed.2025.118687_bib65","author":"Honko"},{"key":"10.1016\/j.socscimed.2025.118687_bib66","article-title":"J&J slashes production of its unpopular Covid-19 shot","author":"Hopkins","year":"2023","journal-title":"Wall St. J."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03085147.2022.2087899","article-title":"More-than-national and less-than-global: the biochemical infrastructure of vaccine manufacturing","volume":"52","author":"Jensen","year":"2022","journal-title":"Econ. Soc."},{"key":"10.1016\/j.socscimed.2025.118687_bib70","article-title":"F.D.A. approves pfizer's R.S.V. vaccine for older adults","author":"Jewett","year":"2023","journal-title":"N. Y. Times"},{"key":"10.1016\/j.socscimed.2025.118687_bib71","series-title":"Dow Jones Institutional News","article-title":"Sufficient number of Crucell holders tender shares","year":"2011"},{"issue":"6","key":"10.1016\/j.socscimed.2025.118687_bib78","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3152\/030234209X460980","article-title":"Multiple institutional rationalities in the regulation of health technologies: an ethnographic examination","volume":"36","author":"Jones","year":"2009","journal-title":"Sci. Publ. Pol."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib79","article-title":"Vaccine apartheid: a human rights analysis of COVID-19 vaccine inequity","volume":"31","author":"Joseph","year":"2022","journal-title":"Florida State Univer. J. Trans. Law Policy"},{"key":"10.1016\/j.socscimed.2025.118687_bib80","series-title":"Biomedical Platforms: Realigning the Normal and the Pathological in late-twentieth-century Medicine","author":"Keating","year":"2003"},{"key":"10.1016\/j.socscimed.2025.118687_bib81","series-title":"Routledge Handbook of Science, Technology and Society","author":"Kleinman","year":"2019"},{"key":"10.1016\/j.socscimed.2025.118687_bib82","series-title":"Johnson & Johnson Chief Looks to the Greater Good","author":"Kuchler","year":"2020"},{"issue":"5","key":"10.1016\/j.socscimed.2025.118687_bib83","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/d41573-022-00035-z","article-title":"The mRNA vaccine development landscape for infectious diseases","volume":"21","author":"Kumar","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.socscimed.2025.118687_bib84","series-title":"The Pasteurization of France","author":"Latour","year":"1993"},{"key":"10.1016\/j.socscimed.2025.118687_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073747","article-title":"US public investment in development of mRNA covid-19 vaccines: retrospective cohort study","author":"Lalani","year":"2023","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.socscimed.2025.118687_bib86","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/03063127221110137","article-title":"Adequate trials: how the search for a cure shaped leukemia diagnosis","volume":"52","author":"Levy","year":"2022","journal-title":"Soc. Stud. Sci."},{"key":"10.1016\/j.socscimed.2025.118687_bib87","series-title":"The Messenger: Moderna, the Vaccine, and the Business Gamble that Changed the World","author":"Loftus","year":"2022"},{"key":"10.1016\/j.socscimed.2025.118687_bib88","article-title":"The new NIH intramural research program access planning policy","author":"Love","year":"2025","journal-title":"Knowled. Ecol. Int."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib90","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14760584.2023.2184803","article-title":"The quest for an HIV-1 vaccine: will mRNA deliver us from evil?","volume":"22","author":"Lusso","year":"2023","journal-title":"Expet Rev. Vaccine"},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00001-0","article-title":"Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan Virus Vaccine: a challenge study in macaques","volume":"4","author":"Marzi","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.socscimed.2025.118687_bib92","author":"McPhillips"},{"key":"10.1016\/j.socscimed.2025.118687_bib93","author":"Mitchell"},{"issue":"15","key":"10.1016\/j.socscimed.2025.118687_bib94","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a Randomized Clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1056\/NEJMp2107528","article-title":"Averting future vaccine injustice","volume":"385","author":"Moon","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"S2","key":"10.1016\/j.socscimed.2025.118687_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1017\/jme.2023.149","article-title":"The NIH-Moderna vaccine: public science, private profit, and lessons for the future","volume":"51","author":"Morten","year":"2023","journal-title":"J. Law Med. Ethics"},{"issue":"16","key":"10.1016\/j.socscimed.2025.118687_bib111","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.89.16.7777","article-title":"Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model","volume":"89","author":"Natuk","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib112","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14760584.2022.2089121","article-title":"Making COVID-19 mRNA vaccines accessible: challenges resolved","volume":"21","author":"Niazi","year":"2022","journal-title":"Expet Rev. Vaccine"},{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib113","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations","volume":"89","author":"O'Brien","year":"2014","journal-title":"Acad. Med."},{"issue":"12","key":"10.1016\/j.socscimed.2025.118687_bib114","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/pathogens11121469","article-title":"Nurturing deep tech to solve social problems: learning from COVID-19 mRNA vaccine development","volume":"11","author":"Okuyama","year":"2022","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.socscimed.2025.118687_bib115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15585\/mmwr.mm7103a4","article-title":"Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: updated Interim Recommendations from the Advisory Committee on Immunization Practices","volume":"71","author":"Oliver","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.socscimed.2025.118687_bib116","series-title":"J&J to Phase out Janssen Name in Corporate Rebrand","author":"Pagliarulo","year":"2023"},{"key":"10.1016\/j.socscimed.2025.118687_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1151713","article-title":"From lab to mass production: a policy for enabling the licensing of mRNA vaccines","volume":"11","author":"Panagopoulos","year":"2023","journal-title":"Front. Public Health"},{"issue":"7","key":"10.1016\/j.socscimed.2025.118687_bib118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.socscimed.2025.118687_bib119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1017\/jme.2023.118","article-title":"The Brazilian pharmaceutical industry: actors, institutions, and policies","volume":"51","author":"Paranhos","year":"2023","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.socscimed.2025.118687_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1065993","article-title":"\u201cA passion to change the landscape and drive a renaissance\u201d: the mRNA hub at Afrigen as decolonial aspiration","volume":"10","author":"Paremoer","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.socscimed.2025.118687_bib121","series-title":"Science Business: the Promise, the Reality, and the Future of Biotech","author":"Pisano","year":"2006"},{"key":"10.1016\/j.socscimed.2025.118687_bib122","unstructured":"Private equity and venture capital success story:Crucell. InvestEurope. (n.d.). https:\/\/www.investeurope.eu\/about-private-equity\/private-equity-in-action\/crucell\/."},{"issue":"S2","key":"10.1016\/j.socscimed.2025.118687_bib123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/jme.2023.155","article-title":"If left unchecked: lessons learned from unfettered U.S. government support of the NIH-Moderna vaccine","volume":"51","author":"Ramachandran","year":"2023","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.socscimed.2025.118687_bib124","series-title":"Capitalizing a Cure: How Finance Controls the Price and Value of Medicines","author":"Roy","year":"2023"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-56293-x","article-title":"Impact of SARS-COV-2 spike stability and RBD exposure on antigenicity and immunogenicity","volume":"14","author":"Rutten","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001272","article-title":"Technologies of trust in epidemic response: openness, reflexivity and accountability during the 2014\u20132016 Ebola outbreak in West Africa","volume":"4","author":"Ryan","year":"2019","journal-title":"BMJ Glob. Health"},{"issue":"23","key":"10.1016\/j.socscimed.2025.118687_bib128","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.socscimed.2025.118687_bib129","series-title":"The History and Political Economy of NIH Peer Review","author":"Sampat","year":"2023"},{"key":"10.1016\/j.socscimed.2025.118687_bib130","article-title":"Withdrawals of COVID-19 biologics should prompt us to reimagine our drug pipeline","author":"Sariahmed","year":"2023","journal-title":"Health Affairs Forefront"},{"key":"10.1016\/j.socscimed.2025.118687_bib131","first-page":"225","article-title":"Development of a national public pharmaceutical research and development institute","volume":"47","author":"Sarpatwari","year":"2019","journal-title":"J. Law Med. Ethics"},{"issue":"S2","key":"10.1016\/j.socscimed.2025.118687_bib132","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/jme.2023.152","article-title":"Public returns on public investment: moderna's violation of the social contract","volume":"51","author":"Sarpatwari","year":"2023","journal-title":"J. Law Med. Ethics"},{"issue":"5908","key":"10.1016\/j.socscimed.2025.118687_bib133","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.socscimed.2025.118687_bib134","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.socscimed.2025.118687_bib135","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/13543776.2021.1945581","article-title":"The patent maze of COVID-19 vaccines","volume":"31","author":"Storz","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.socscimed.2025.118687_bib136","author":"Stulpin"},{"issue":"6812","key":"10.1016\/j.socscimed.2025.118687_bib137","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"issue":"6949","key":"10.1016\/j.socscimed.2025.118687_bib138","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.socscimed.2025.118687_bib140","article-title":"Which Covid-19 vaccine saved the most lives in 2021?","year":"2022","journal-title":"Economist"},{"issue":"10","key":"10.1016\/j.socscimed.2025.118687_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00328-5","article-title":"From private incentives to public health need: rethinking research and development for pandemic preparedness","volume":"11","author":"Torreele","year":"2023","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib143","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"16","key":"10.1016\/j.socscimed.2025.118687_bib148","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"41","key":"10.1016\/j.socscimed.2025.118687_bib149","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.socscimed.2025.118687_bib150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: a Snapshot","volume":"17","author":"Woolsey","year":"2021","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.socscimed.2025.118687_bib152","first-page":"197","article-title":"Weekly epidemiological record","volume":"96","year":"2021","journal-title":"Week. Epidemiol. Record"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib154","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib155","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.socscimed.2025.118687_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2021","journal-title":"Bioeng. Transl. Med."},{"issue":"9","key":"10.1016\/j.socscimed.2025.118687_bib157","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/vaccines10091458","article-title":"Durability of protection post\u2013primary COVID-19 vaccination in the United States","volume":"10","author":"Zheutlin","year":"2022","journal-title":"Vaccines"}],"container-title":["Social Science & Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0277953625010184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0277953625010184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:24:30Z","timestamp":1780820670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0277953625010184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":117,"alternative-id":["S0277953625010184"],"URL":"https:\/\/doi.org\/10.1016\/j.socscimed.2025.118687","relation":{},"ISSN":["0277-9536"],"issn-type":[{"value":"0277-9536","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public sector innovation and the constraints of \u2018platform thinking\u2019: An account of Johnson & Johnson's adenoviral vector vaccines","name":"articletitle","label":"Article Title"},{"value":"Social Science & Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.socscimed.2025.118687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118687"}}